France-based medtech company Defymed said today that it’s developing a novel insulin delivery device which it hopes to bring to market by the end of 2020.
The company’s device, ExOlin, uses a biocompatible membrane that is nonbiodegradable and permeable to insulin, according to Defymed. The insulin delivery device is designed to be implanted into a patient’s abdomen and to facilitate insulin delivery through a simple injection. Patients with diabetes can continue their normal insulin delivery methods, Defymed said, and use ExOlin to better stabilize their blood sugar levels over an extended length of time.
Get the full story at our sister site, Drug Delivery Business News.
The post Defymed reveals development of novel insulin delivery device appeared first on MassDevice.